☰

Kamlesh S. Sodani, Ph.D. - Publications

Affiliations: 
2013 Pharmaceutical Sciences St. John's University (New York), School of Pharmacy 
Area:
Oncology, Pharmacology
Tree Info Grants Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Zhang DM, Shu C, Chen JJ, Sodani K, Wang J, Bhatnagar J, Lan P, Ruan ZX, Xiao ZJ, Ambudkar SV, Chen WM, Chen ZS, Ye WC. Correction to "BBA, a Derivative of 23-Hydroxybetulinic Acid, Potently Reverses ABCB1-Mediated Drug Resistance and ". Molecular Pharmaceutics. 20: 3249. PMID 37183880 DOI: 10.1021/acs.molpharmaceut.3c00215  0.602
2017 Patel A, Li TW, Anreddy N, Wang DS, Sodani K, Gadhia S, Kathawala R, Yang DH, Cheng C, Chen ZS. Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. Pharmacological Research. PMID 28455266 DOI: 10.1016/J.Phrs.2017.04.025  0.85
2016 Whitt JD, Keeton AB, Gary BD, Sklar LA, Sodani K, Chen ZS, Piazza GA. Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. Journal of Biomedical Research. 30: 120-133. PMID 28276667 DOI: 10.7555/Jbr.30.20150108  0.745
2015 Kathawala RJ, Wei L, Anreddy N, Chen K, Patel A, Alqahtani S, Zhang YK, Wang YJ, Sodani K, Kaddoumi A, Ashby CR, Chen ZS. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget. 6: 510-21. PMID 25402202 DOI: 10.18632/Oncotarget.2638  0.844
2014 Anreddy N, Patel A, Sodani K, Kathawala RJ, Chen EP, Wurpel JN, Chen ZS. PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharmaceutica Sinica. B. 4: 202-207. PMID 26579384 DOI: 10.1016/J.Apsb.2014.02.003  0.802
2014 Zhang H, Zhang YK, Wang YJ, Kathawala RJ, Patel A, Zhu H, Sodani K, Talele TT, Ambudkar SV, Chen ZS, Fu LW. WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells. Cancer Science. 105: 1071-8. PMID 24903205 DOI: 10.1111/Cas.12462  0.831
2014 Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical Pharmacology. 89: 52-61. PMID 24565910 DOI: 10.1016/J.Bcp.2014.02.012  0.855
2014 Sun YL, Kumar P, Sodani K, Patel A, Pan Y, Baer MR, Chen ZS, Jiang WQ. Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncology Reports. 31: 1605-12. PMID 24481648 DOI: 10.3892/Or.2014.3002  0.865
2014 Kathawala RJ, Sodani K, Chen K, Patel A, Abuznait AH, Anreddy N, Sun YL, Kaddoumi A, Ashby CR, Chen ZS. Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study. Molecular Cancer Therapeutics. 13: 714-23. PMID 24431074 DOI: 10.1158/1535-7163.Mct-13-0743  0.85
2014 Guo HQ, Zhang GN, Wang YJ, Zhang YK, Sodani K, Talele TT, Ashby CR, Chen ZS. β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. Oncology Reports. 31: 858-66. PMID 24284783 DOI: 10.3892/Or.2013.2870  0.63
2014 Sodani K, Tiwari AK, Dai C, Abuznait AH, Patel A, Xiao Z, Ashby CR, Kaddoumi A, Fu L, Chen Z. Sildenafil Enhances the Anticancer Activity of Paclitaxel in an ABCB1-Mediated Multidrug Resistance Xenograft Mouse Model Journal of Cancer Research Updates. 3: 169-173. DOI: 10.6000/1929-2279.2014.03.03.7  0.844
2014 Kathawala R, Sodani K, Chen K, Patel A, Abuznait A, Anreddy N, Sun Y, Kaddoumi A, Ashby CR, Chen Z. Abstract 1964: Masitinib antagonizes ATP-binding cassette subfamily c member 10-mediated paclitaxel resistance: a preclinical study Cancer Research. 74: 1964-1964. DOI: 10.1158/1538-7445.Am2014-1964  0.856
2013 Chen JJ, Patel A, Sodani K, Xiao ZJ, Tiwari AK, Zhang DM, Li YJ, Yang DH, Ye WC, Chen SD, Chen ZS. bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). Plos One. 8: e74573. PMID 24069321 DOI: 10.1371/Journal.Pone.0074573  0.834
2013 Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R, Chen ZS. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemotherapy and Pharmacology. 72: 189-99. PMID 23673445 DOI: 10.1007/S00280-013-2184-Z  0.825
2013 Sun YL, Chen JJ, Kumar P, Chen K, Sodani K, Patel A, Chen YL, Chen SD, Jiang WQ, Chen ZS. Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. Plos One. 8: e55576. PMID 23393594 DOI: 10.1371/Journal.Pone.0055576  0.844
2013 Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Patel A, Talele TT, Fu L, Kaddoumi A, Gallo JM, Chen ZS. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Letters. 328: 307-17. PMID 23063650 DOI: 10.1016/J.Canlet.2012.10.001  0.828
2013 Liu KJ, He JH, Su XD, Sim HM, Xie JD, Chen XG, Wang F, Liang YJ, Singh S, Sodani K, Talele TT, Ambudkar SV, Chen ZS, Wu HY, Fu LW. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. International Journal of Cancer. Journal International Du Cancer. 132: 224-35. PMID 22623106 DOI: 10.1002/Ijc.27649  0.763
2013 Vispute SG, Chen J, Sun Y, Sodani KS, Singh S, Pan Y, Talele T, Ashby CR, Chen Z. Vemurafenib (PLX4032, Zelboraf®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance Journal of Cancer Research Updates. 2: 306-317. DOI: 10.6000/1929-2279.2013.02.04.9  0.778
2013 Sodani K, Tiwari AK, Dai C, Abuznait AH, Xiao Z, Kaddouni A, Chen Z. Abstract 986: Sildenafil potentiates the anticancer activity of paclitaxel in ABCB1-mediated multidrug resistance xenograft model. Cancer Research. 73: 986-986. DOI: 10.1158/1538-7445.Am2013-986  0.764
2013 Patel AS, Tiwari A, Chufan E, Singh S, Sodani K, Anreddy N, Talele T, Ambudkar S, Stephani R, Chen Z. Abstract 980: PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Research. 73: 980-980. DOI: 10.1158/1538-7445.Am2013-980  0.705
2012 Li T, Yang Y, Cheng C, Tiwari AK, Sodani K, Zhao Y, Abraham I, Chen ZS. Design, synthesis and biological evaluation of N-arylphenyl-2,2-dichloroacetamide analogues as anti-cancer agents. Bioorganic & Medicinal Chemistry Letters. 22: 7268-71. PMID 23067553 DOI: 10.1016/J.Bmcl.2012.07.057  0.681
2012 Zhang DM, Shu C, Chen JJ, Sodani K, Wang J, Bhatnagar J, Lan P, Ruan ZX, Xiao ZJ, Ambudkar SV, Chen WM, Chen ZS, Ye WC. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Molecular Pharmaceutics. 9: 3147-59. PMID 23046348 DOI: 10.1021/Mp300249S  0.748
2012 Kuang YH, Patel JP, Sodani K, Wu CP, Liao LQ, Patel A, Tiwari AK, Dai CL, Chen X, Fu LW, Ambudkar SV, Korlipara VL, Chen ZS. OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochemical Pharmacology. 84: 766-74. PMID 22750060 DOI: 10.1016/J.Bcp.2012.06.019  0.838
2012 Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Yang DH, Vispute SG, Jiang WQ, Chen SD, Chen ZS. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Science. 103: 1531-7. PMID 22578167 DOI: 10.1111/J.1349-7006.2012.02328.X  0.767
2012 Sodani K, Tiwari AK, Singh S, Patel A, Xiao ZJ, Chen JJ, Sun YL, Talele TT, Chen ZS. GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochemical Pharmacology. 83: 1613-22. PMID 22414725 DOI: 10.1016/J.Bcp.2012.02.028  0.856
2012 Sodani K, Patel A, Kathawala RJ, Chen ZS. Multidrug resistance associated proteins in multidrug resistance. Chinese Journal of Cancer. 31: 58-72. PMID 22098952 DOI: 10.5732/Cjc.011.10329  0.833
2012 Sodani KS, Tiwari AK, Singh S, Patel A, Xiao Z, Chen J, Sun Y, Talele TT, Chen Z. Abstract 777: GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance Cancer Research. 72: 777-777. DOI: 10.1158/1538-7445.Am2012-777  0.846
2011 Tiwari AK, Sodani K, Dai CL, Ashby CR, Chen ZS. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Current Pharmaceutical Biotechnology. 12: 570-94. PMID 21118094 DOI: 10.2174/138920111795164048  0.724
2011 Patel JP, Kuang Y, Sodani K, Wu C, Liao L, Tiwari AK, Dai C, Chen X, Fu L, Ambudkar SV, Korlipara VL, Chen Z. Abstract 1740: Analogs of OSI-930 as potent ABCG2-mediated multidrug resistance reversal agents Cancer Research. 71: 1740-1740. DOI: 10.1158/1538-7445.Am2011-1740  0.75
2010 Kuang YH, Shen T, Chen X, Sodani K, Hopper-Borge E, Tiwari AK, Lee JW, Fu LW, Chen ZS. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochemical Pharmacology. 79: 154-61. PMID 19720054 DOI: 10.1016/J.Bcp.2009.08.021  0.767
2010 Tiwari AK, Sodani K, Wang S, Kuang Y, Deng W, Chen X, Chen K, Ashby CR, Chen Z. Abstract 1531: BCR-Abl tyrosine kinase inhibitor Nilotinib (Tasigna®) reverses ABCB1/Pgp- and ABCG2/BCRP-mediated multidrug resistance Cancer Research. 70: 1531-1531. DOI: 10.1158/1538-7445.Am10-1531  0.792
2010 Sodani K, Kuang Y, Shen T, Vispute S, Tiwari AK, Lei Y, Lee J, Chen X, Ashby CR, Chen Z. Abstract 1519: Tyrosine kinase inhibitors are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance Cancer Research. 70: 1519-1519. DOI: 10.1158/1538-7445.Am10-1519  0.776
2009 Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR, Chen X, Chen ZS. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochemical Pharmacology. 78: 153-61. PMID 19427995 DOI: 10.1016/J.Bcp.2009.04.002  0.793
Show low-probability matches.